Compare Coupang Inc (CPNG) vs Revvity Inc (RVTY) Price & Performance

Coupang (CPNG) trades at $15.82, up 6.82% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with positive moving averages and institutional support. Revenue growth remains robust at $34.53 billion for 2025, though profitability metrics show challenges with negative net income margin and ROE. Analyst consensus is strongly bullish with 87.5% buy ratings and a $25.25 price target, representing significant upside potential from current levels.

The investment case hinges on Coupang's dominant South Korean market position and expanding logistics network, but faces headwinds from inconsistent profitability and competitive pressures. While valuation appears reasonable on sales (P/S 0.8), high P/E ratio reflects earnings volatility. Key risks include execution challenges in international expansion and margin pressure from logistics investments. The stock offers growth exposure but requires careful monitoring of profitability trends.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.